Morand EF, Furie R, Tanaka Y, et al. - All individuals (n = 362) were randomized in a 1:1 ratio to receive intravenous anifrolumab (300 mg, n = 180) or placebo (n = 182) every 4 weeks for 48 weeks in order to determine the effect of anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 examined for the treatment of SLE. At week 52, the monthly administration of anifrolumab led to a greater percentage of people with a response (as defined by a composite endpoint), compared with placebo, in contrast to the findings of a comparable phase 3 trial involving people with SLE that had a distinctive primary endpoint. Moreover, the frequency of herpes zoster was greater with anifrolumab vs placebo.